Our firm provided comprehensive legal counsel to a leading Chinese specializing in cell and gene therapy. We assisted in the registration of their subsidiary, ensuring full compliance with all regulatory requirements and facilitating a smooth establishment process. Our work drew on regional precedent and compliance modeling similar to our Ukrainian IT advisory, where speed and legal certainty were paramount during cross-border corporate setup.
Additionally, we advised the company on successfully closing a significant Series C+ funding round, securing over 100 million RMB. This funding transaction paralleled key mandates in our biotech legal support, where regulatory alignment and capital structuring were critical to unlocking growth rounds. This landmark investment strengthens their position as a frontrunner in gene therapy delivery.
The client offers economical, reliable, and scalable viral and non-viral vector solutions, including platforms for plasmid DNA, AAV, lentivirus, and mRNA manufacturing. Their services support programs from early-stage R&D and preclinical development through to clinical trials. With similar biotech frameworks gaining regulatory traction, insights from qualified investor fund regimes also contributed to structuring guidance on long-term asset flows and eligibility compliance.
Our legal support encompassed corporate structuring, regulatory compliance, and transaction advisory, contributing to their continued growth and success in the biotech industry. Our approach reflects the high standards recognized in the IFLR1000 rankings 2024, validating the firm’s leading position in biotech and cross-border advisory mandates. The transaction and investment structuring approach also aligned with practices seen in high-stakes US acquisition legal support, particularly in aligning capital flows with regulatory clarity.
Industry sector: Biotechnology / Medicine
Deal value: 100 000 000 EUR
